Abstract
Lysophosphatidic acid (LPA) is a potent lipid mediator with diverse physiological actions on a wide variety of cells and tissues. Three cognate G-protein-coupled receptors have been identified as mammalian LPA receptors: LPA1/VZG-1/EDG-2, LPA2/EDG-4, and LPA3/EDG-7. The mouse forms of these genes were analyzed in rodent cell lines derived from nervous system cells that can express these receptors functionally. An efficient retrovirus expression system was used, and each receptor was heterologously expressed in B103 rat neuroblastoma cells that neither express these receptors nor respond to LPA in all assays tested. Comparative analyses of signaling pathways that are activated within minutes of ligand delivery were carried out. LPA induced cell rounding in LPA1- and LPA2-expressing cells. By contrast, LPA3 expression resulted in neurite elongation in B103 cells and inhibited LPA-dependent cell rounding in TR mouse neuroblast cells that endogenously express LPA1 and LPA2but not LPA3. Each of the receptors could couple to multiple G-proteins and induced LPA-dependent inositol phosphate production, mitogen-activated protein kinase activation, and arachidonic acid release while inhibiting forskolin-induced cAMP accumulation, although the efficacy and potency of LPA varied from receptor to receptor. These results indicate both shared and distinct functions among the three mammalian LPA receptors. The retroviruses developed in this study should provide tools for addressing these functions in vivo.
Footnotes
- Received May 15, 2000.
- Accepted August 2, 2000.
-
Send reprint requests to: Jerold Chun, M.D., Ph.D.. Department of Pharmacology, School of Medicine, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0636. E-mail: jchun{at}ucsd.edu
-
This work was supported by the National Institute of Mental Health (R01 MH51699) and the National Institutes of Health (K02 MH01723) (to J.C.). I.I. and N.F. are supported by the Uehara Memorial Foundation.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|